Prof. R. StephanieHuang – Oncology and Precision Medicine – Best Researcher Award 

Posted on by Pencis

Prof. R. StephanieHuang - Oncology and Precision Medicine - Best Researcher Award 

University Of Minnesota - Minneapolis, MN - United States

Author Profile

Scopus 

Orcid

Early Academic Pursuits

Dr. Rong Stephanie Huang's academic journey began with her pursuit of pharmacology at the University of Minnesota, where she eventually earned the title of Distinguished McKnight University Professor. Her early academic pursuits laid the foundation for her distinguished career in the field.

Professional Endeavors

Throughout her career, Dr. Huang has held prestigious academic appointments, including her current position in the Department of Experimental and Clinical Pharmacology at the University of Minnesota. Her commitment to advancing pharmacology is evident in her leadership roles and contributions to various professional societies.

Contributions and Research Focus on Oncology and Precision Medicine

Dr. Huang's research primarily focuses on personalized and precision medicine, particularly in oncology. Her work aims to tailor treatments to individual patients by understanding the genetic and molecular mechanisms underlying cancer progression. This research has significant implications for improving patient outcomes in cancer treatment.

Impact and Influence

As a respected leader in pharmacology, Dr. Huang's influence extends beyond her research. Her leadership roles in organizations such as the International Pharmaceutical Federation (FIP) highlight her dedication to advancing the field on a global scale. Her contributions have shaped the landscape of personalized medicine and oncology research.

Academic Citations

Dr. Huang's research has garnered substantial attention within the academic community, evidenced by the numerous citations her work has received. Her findings have contributed to advancing knowledge in pharmacology, particularly in the realm of personalized medicine and cancer research.

Legacy and Future Contributions

Dr. Huang's legacy is characterized by her significant contributions to pharmacology and personalized medicine. Her ongoing leadership roles and mentorship efforts ensure that her impact will endure for future generations of pharmacologists. As she continues her research and advocacy, Dr. Huang will undoubtedly leave a lasting legacy in the field.

Notable Publications

Computational Modeling to Identify Drugs Targeting Metastatic Castration-Resistant Prostate Cancer Characterized by Heightened Glycolysis.

Integration of Computational Pipeline to Streamline Efficacious Drug Nomination and Biomarker Discovery in Glioblastoma.

Integration of pan-cancer cell line and single-cell transcriptomic profiles enables inference of therapeutic vulnerabilities in heterogeneous tumors.

A review of computational methods for predicting cancer drug response at the single-cell level through integration with bulk RNAseq data.

 

 

 

Ms Menekse Turna – Radiation Oncology – Best Researcher Award

Posted on by Pencis

Ms Menekse Turna - Radiation Oncology - Best Researcher Award

Anadolu Medical Center - Turkey

AUTHOR PROFILE

Orchid

Scopus

Early Academic Pursuits

Menekşe Turna began her academic journey with a strong foundation at the Karadeniz Technical University Faculty Of Medicine in Trabzon, Turkey, where she dedicated six years of study from 2005 to 2011. This period laid the groundwork for her future contributions in the field of medicine.

Professional Endeavors

Upon completing her medical education, Menekşe Turna delved into the specialized field of Radiation Oncology. She started her professional journey at Okmeydani Research and Training Hospital in Istanbul, where she gained valuable experience from 2012 to 2016. Later, she expanded her horizons by joining the St James Institute of Oncology in Leeds, England, as a Clinical Observer in 2015-2016, further enriching her knowledge in the international medical landscape.

Contributions and Research Focus on Radiation oncology

Menekşe Turna's primary focus in Radiation Oncology showcases her commitment to advancing cancer treatment. Her contributions to the field involve a keen interest in therapeutic radiology, emphasizing precision and efficacy in cancer treatment methods. Through her work, she aims to contribute to the ongoing advancements in radiation therapy for improved patient outcomes.

Academic Cites

Menekşe Turna's academic achievements are reflected in her successful completion of the Second degree in the Board Exam of the Turkish Society for Radiation Oncology in 2016. This recognition signifies her expertise and proficiency in the field.

Legacy and Future Contributions

As a dedicated medical professional, Menekşe Turna is already leaving a positive mark on the field of Radiation Oncology. Her legacy lies in the lives she impacts through precise and compassionate cancer care. Looking forward, she envisions continued contributions to research, education, and patient care, leaving an enduring legacy in the medical community.

NOTABLE PUBLICATIONS

Stereotactic radiosurgery in brain metastasis: treatment outcomes and patterns of failure.2023

Evaluation of clinically involved lymph nodes with deformable registration in breast cancer radiotherapy.2022

Stereotactic body radiotherapy as a boost after external beam radiotherapy for high-risk prostate cancer patients.2021

 

Biomedical Advancements in Cancer

Posted on by Pencis

Biomedical Advancements in Cancer

 

Introduction: In recent years, the field of biomedical advancements in cancer research has witnessed remarkable breakthroughs that have transformed our understanding of the disease and revolutionized treatment options. These advancements offer new hope to patients and hold the promise of improved outcomes in the fight against cancer.

Subtopics in Biomedical Advancements in Cancer:

Immunotherapy and Immune Checkpoint Inhibitors: Immune checkpoint inhibitors have emerged as a game-changer in cancer treatment, leveraging the body’s immune system to target and eliminate cancer cells. CAR-T cell therapy, PD-1 inhibitors, and CTLA-4 inhibitors are some of the key developments in this area.

Precision Medicine and Genomic Profiling: Advancements in genomic sequencing technologies have paved the way for precision medicine in cancer treatment. Tailoring therapies based on the genetic makeup of a patient’s tumor has improved treatment efficacy and reduced side effects.

Liquid Biopsies for Early Detection: Liquid biopsies involve the non-invasive analysis of blood or other bodily fluids to detect cancer-related genetic mutations and biomarkers. These tests offer early detection capabilities and real-time monitoring of cancer progression.

Targeted Therapies and Personalized Cancer Drugs: Targeted therapies are designed to specifically inhibit the molecular pathways driving cancer growth. Advances in drug development have led to a wide range of targeted treatments, enhancing the effectiveness of cancer therapy while minimizing collateral damage to healthy cells.

AI and Machine Learning in Cancer Diagnosis and Treatment: Artificial intelligence and machine learning algorithms are being employed to analyze vast datasets of medical information, aiding in early cancer diagnosis, treatment planning, and predicting patient outcomes. These technologies have the potential to optimize cancer care and streamline research efforts.

These subtopics represent just a fraction of the exciting developments in the biomedical field related to cancer research. Continued research and innovation in these areas are bringing us closer to more effective treatments, early detection methods, and improved patient outcomes in the battle against cancer.